Boehringer Ingelheim Adds $149 Million to its Investment in China

Boehringer Ingelheim of Germany will invest $149 million in China with the goal of increasing its market share in China’s pharmaceutical market. The company will use the money to expand the capacity at its existing drug production facility in Shanghai's Zhangjiang High-Tech Park, and it will also establish an R&D facility. More details...